BRPI0610780A2 - formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete - Google Patents
formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tableteInfo
- Publication number
- BRPI0610780A2 BRPI0610780A2 BRPI0610780A BRPI0610780A BRPI0610780A2 BR PI0610780 A2 BRPI0610780 A2 BR PI0610780A2 BR PI0610780 A BRPI0610780 A BR PI0610780A BR PI0610780 A BRPI0610780 A BR PI0610780A BR PI0610780 A2 BRPI0610780 A2 BR PI0610780A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulation
- tablet pharmaceutical
- patient
- treating
- producing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67407705P | 2005-04-22 | 2005-04-22 | |
PCT/US2006/013516 WO2006115770A2 (en) | 2005-04-22 | 2006-04-11 | Orally disintegrating pharmaceutical tablet formulations of olanzapine |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0610780A2 true BRPI0610780A2 (pt) | 2016-09-06 |
Family
ID=37215208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0610780A BRPI0610780A2 (pt) | 2005-04-22 | 2006-04-11 | formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060240101A1 (pt) |
JP (1) | JP2008536922A (pt) |
BR (1) | BRPI0610780A2 (pt) |
PL (1) | PL385455A1 (pt) |
WO (1) | WO2006115770A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI383809B (zh) * | 2005-06-29 | 2013-02-01 | Otsuka Pharma Co Ltd | 含有西洛他唑(cilostazol)之口腔崩解粉末 |
ES2531929T3 (es) * | 2006-12-20 | 2015-03-20 | Teva Women's Health, Inc. | Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas |
EP2471516A3 (en) | 2007-09-14 | 2012-12-26 | Wockhardt Limited | Rhein or diacerein compositions |
WO2011087705A2 (en) * | 2009-12-22 | 2011-07-21 | Fmc Corporation | Fine particle croscarmellose and uses thereof |
US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
CN102440974B (zh) * | 2011-12-27 | 2013-11-27 | 天津市嵩锐医药科技有限公司 | 奥氮平口腔崩解药物组合物 |
CN102631331A (zh) * | 2012-04-26 | 2012-08-15 | 北京哈三联科技股份有限公司 | 奥氮平口腔崩解片制剂及其制备方法 |
JP2014218472A (ja) * | 2013-05-10 | 2014-11-20 | エルメッド エーザイ株式会社 | オランザピン乃至その塩含有錠剤 |
CN111836615A (zh) | 2018-01-05 | 2020-10-27 | 英倍尔药业股份有限公司 | 通过精密鼻装置的奥氮平的鼻内递送 |
CN113730365A (zh) * | 2021-08-10 | 2021-12-03 | 杭州新诺华医药有限公司 | 一种奥氮平口腔崩解片及其制备方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3653914A (en) * | 1970-03-20 | 1972-04-04 | Alberto Culver Co | Production of tablets |
US4091091A (en) * | 1973-11-08 | 1978-05-23 | Eli Lilly And Company | Stabilized nitroglycerin tablets |
US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
US4327076A (en) * | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4866046A (en) * | 1988-05-31 | 1989-09-12 | Top Laboratories, Inc. | Low-dosage sublingual aspirin |
US5082667A (en) * | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
US5122384A (en) * | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
CA2061520C (en) * | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
EP0553777B1 (en) * | 1992-01-29 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
CA2130487A1 (en) * | 1992-02-18 | 1993-08-19 | Kouichi Nakamichi | Fast soluble tablet |
US5780051A (en) * | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
JPH06218028A (ja) * | 1992-10-02 | 1994-08-09 | Eisai Co Ltd | 湿製錠の成型方法とその装置及び湿製錠 |
US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5851553A (en) * | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5965162A (en) * | 1993-09-10 | 1999-10-12 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5935600A (en) * | 1993-09-10 | 1999-08-10 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing comestible unit and product therefrom |
US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
US5609883A (en) * | 1994-09-16 | 1997-03-11 | Advanced Technology Pharmaceuticals Corporation | Compressed tablet transitory lubricant system |
CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
BR9611815A (pt) * | 1995-07-31 | 1999-10-13 | Gergely Gerhard | Tablete de mascar com ação efervescente |
US5762961A (en) * | 1996-02-09 | 1998-06-09 | Quadrant Holdings Cambridge Ltd. | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof |
US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
JP2000095674A (ja) * | 1998-09-22 | 2000-04-04 | Sato Pharmaceutical Co Ltd | 口腔内崩壊時間短縮化錠剤の製造方法及び装置 |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6863901B2 (en) * | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
US20040265375A1 (en) * | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
-
2006
- 2006-04-11 BR BRPI0610780A patent/BRPI0610780A2/pt not_active IP Right Cessation
- 2006-04-11 US US11/402,416 patent/US20060240101A1/en not_active Abandoned
- 2006-04-11 PL PL385455A patent/PL385455A1/pl not_active Application Discontinuation
- 2006-04-11 WO PCT/US2006/013516 patent/WO2006115770A2/en active Search and Examination
- 2006-04-11 JP JP2008507712A patent/JP2008536922A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006115770A2 (en) | 2006-11-02 |
WO2006115770A3 (en) | 2007-11-29 |
JP2008536922A (ja) | 2008-09-11 |
US20060240101A1 (en) | 2006-10-26 |
PL385455A1 (pl) | 2008-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0610780A2 (pt) | formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete | |
NO2014028I2 (no) | Glukopyranosyl-substituerte benzenderivater, fremgangsmåte for fremstilling av disse, fysiologisk akseptable salter av slike forbindelser, medikamenter inneholdende slike forbindelser og kombinasjoner med andre aktive substanser samt deresanvendelse for fremstilling av medikamenter for behandling av sykdom | |
HK1137352A1 (en) | Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent | |
BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
GB0412753D0 (en) | Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis | |
BRPI0917119A2 (pt) | composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação. | |
HK1129844A1 (en) | Use of l-cytosine nucleoside analogs in the manufacture of a medicament for use in treating cancer and other conditions or disease states l- | |
LT1965816T (lt) | Farmacinės kompozicijos ir metodai, skirti su oksalatu susijusių ligų gydymui arba prevencijai | |
ZA200802897B (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease | |
EP2046973A4 (en) | METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY | |
BRPI0816255A2 (pt) | Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável | |
IL189500A (en) | 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p | |
BRPI0607198A2 (pt) | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica | |
IL206296A (en) | History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases | |
EP1985302A4 (en) | DRUGS FOR TUMOR THERAPY AND ITS USE | |
BRPI0813513A2 (pt) | Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer | |
IL193094A (en) | Appalidine and other drugs used in the manufacture of a cancer treatment drug when the combination of the two gives a synergistic result | |
BRPI0909651A2 (pt) | cristal, agente farmacêutico, método para tratar ou evitar doença, uso do cristal, e, método para a produção de um cristal | |
PT2054045E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor | |
IL179473A0 (en) | Pharmaceutical products for treating neoplastic disease and inflammation | |
IL194880A (en) | Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them | |
IL205290A (en) | A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs | |
BRPI0612624A2 (pt) | métodos para tratar doença vascular em um humano, e para prevenção e/ou tratamento de uma doença induzida por trombose ou uma doença induzida por tromboembolismo em um humano, e, uso de um composto | |
IL195155A (en) | Dosage form for delayed glucocorticoid release and its use in the treatment of rheumatic diseases | |
IL184697A (en) | Diclofenac Injection Composition, Process for its Preparation and Use for Medication and Pain Relief and / or Inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: CONFORME PARECER/INPI/PROC/DIRAD NO18/08 APRESENTE DOCUMENTO DE PROCURACAO DEVIDAMENTE AUTENTICADO OUTORGADO EM DATA ANTERIOR OU COINCIDENTE A DO PRIMEIRO ATO DA PARTE NO PROCESSO, COMPROVANDO PODERES PARA REPRESENTAR O DEPOSITANTE PERANTE O INPI A EPOCA DO DEPOSITO. |
|
B06J | Correction of requirement [chapter 6.10 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 020070148265 DE 19/10/2007. |
|
B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI- LBC-1.0. |
|
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI- LBC-1.0. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |